文献速递真菌感染

耳念珠菌血流感染与其他念珠菌血流感染的结局比较:多中心回顾性病例对照研究

Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

这项在纽约布鲁克林3家医院开展的多中心回顾性病例对照研究纳入196例接受棘白菌素经验性治疗的念珠菌血流感染成人患者,其中耳念珠菌血流感染83例。经逆概率调整后,耳念珠菌血流感染与30天死亡率(调整OR 1.014,95%CI 0.563-1.828,P=0.96)及90天死亡率(调整OR 0.863,95%CI 0.478-1.558,P=0.62)升高无关,但抗真菌治疗结束后60天内微生物学复发风险更高(调整OR 4.461,95%CI 1.033-19.263,P=0.045)。

要点

  • 耳念珠菌血流感染与其他念珠菌血流感染的30天死亡率无显著差异(调整OR 1.014,P=0.96)。
  • 耳念珠菌血流感染的90天死亡率与其他念珠菌血流感染无显著差异(调整OR 0.863,P=0.62)。
  • 耳念珠菌血流感染抗真菌治疗结束后60天内微生物学复发风险更高(调整OR 4.461,P=0.045)。

核心结论

  • 耳念珠菌血流感染与由其他念珠菌引起的血流感染相比,死亡风险未升高。
  • 耳念珠菌组的微生物学复发率更高。

研究设计与样本

  • 在纽约布鲁克林3家医院于2016年至2020年间开展的多中心回顾性病例对照研究。
  • 纳入年龄≥18岁、任何念珠菌血培养阳性且接受棘白菌素经验性治疗的患者。
  • 最终分析共纳入196例患者,其中83例为耳念珠菌血流感染。

主要发现

  • 经逆概率调整后,耳念珠菌血流感染与30天死亡率无关(调整OR 1.014,95%CI 0.563-1.828,P=0.96)。
  • 经逆概率调整后,耳念珠菌血流感染与90天死亡率无关(调整OR 0.863,95%CI 0.478-1.558,P=0.62)。
  • 在抗真菌治疗结束后60天内,耳念珠菌血流感染患者的微生物学复发风险更高(调整OR 4.461,95%CI 1.033-19.263,P=0.045)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study was performed to compare clinical characteristics and outcomes between patients with bloodstream infections (BSIs) caused by Candida auris and those with BSIs caused by other Candida spp. METHODS: A multicenter retrospective case-control study was performed at 3 hospitals in Brooklyn, New York, between 2016 and 2020. The analysis included patients ≥18 years of age who had a positive blood culture for any Candida spp. and were treated empirically with an echinocandin. The primary outcome was the 30-day mortality rate. Secondary outcomes were 14-day clinical failure, 90-day mortality rate, 60-day microbiologic recurrence, and in-hospital mortality rate. RESULTS: A total of 196 patients were included in the final analysis, including 83 patients with candidemia caused by C. auris. After inverse propensity adjustment, C. auris BSI was not associated with increased 30-day (adjusted odds ratio, 1.014 [95% confidence interval, .563-1.828]); P = .96) or 90-day (0.863 [.478-1.558]; P = .62) mortality rates. A higher risk for microbiologic recurrence within 60 days of completion of antifungal therapy was observed in patients with C. auris candidemia (adjusted odds ratio, 4.461 [95% confidence interval, 1.033-19.263]; P = .045). CONCLUSIONS: C. auris BSIs are not associated with a higher mortality risk than BSIs caused by other Candida spp. The rate of microbiologic recurrence was higher in the C. auris group.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Simon SP, Li R, Silver M, et al. Comparative Outcomes of Candida auris Bloodstream Infections: A Multicenter Retrospective Case-Control Study. Clin Infect Dis. 2023. PMID: 36062367. doi:10.1093/cid/ciac735

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。